M
Martin Steins
Researcher at Heidelberg University
Publications - 56
Citations - 11813
Martin Steins is an academic researcher from Heidelberg University. The author has contributed to research in topics: Lung cancer & Nivolumab. The author has an hindex of 22, co-authored 56 publications receiving 9764 citations. Previous affiliations of Martin Steins include University Hospital Heidelberg & Sarah Cannon Research Institute.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone,Martin Reck,Luis Paz-Ares,Benjamin C. Creelan,Leora Horn,Martin Steins,Enriqueta Felip,Michel M. van den Heuvel,Tudor-Eliade Ciuleanu,Firas Benyamine Badin,Neal Ready,T. Jeroen N. Hiltermann,Suresh G. Nair Md,Rosalyn A. Juergens,Solange Peters,Elisa Minenza,John Wrangle,Delvys Rodriguez-Abreu,Hossein Borghaei,George R. Blumenschein,Liza C. Villaruz,Libor Havel,Jana Krejci,Jesus Corral Jaime,Han Chang,William J. Geese,Prabhu Bhagavatheeswaran,Allen C. Chen,Mark A. Socinski +28 more
TL;DR: Nivolumab was not associated with significantly longer progression‐free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD‐L1 expression level of 5% or more.
Journal ArticleDOI
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Leora Horn,David R. Spigel,Everett E. Vokes,Esther Holgado,Neal Ready,Martin Steins,Elena Poddubskaya,Hossein Borghaei,Enriqueta Felip,Luis Paz-Ares,Adam Pluzanski,Karen L. Reckamp,Marco Angelo Burgio,Martin Kohlhaeufl,David M. Waterhouse,Fabrice Barlesi,Scott J. Antonia,Oscar Arrieta,Jérôme Fayette,Lucio Crinò,Naiyer A. Rizvi,Martin Reck,Matthew D. Hellmann,William J. Geese,Ang Li,Anne Blackwood-Chirchir,Diane Healey,Julie R. Brahmer,Wilfried Eberhardt +28 more
TL;DR: Nivolumab provides long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previously treated patients with advanced NSCLC and is reported on in a pooled analysis of the two studies.
Journal ArticleDOI
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Everett E. Vokes,Neal Ready,Enriqueta Felip,Leora Horn,Marco Angelo Burgio,S.J. Antonia,O. Aren Frontera,Scott N. Gettinger,Esther Holgado,David R. Spigel,David M. Waterhouse,Manuel Domine,Marina Chiara Garassino,Laura Q.M. Chow,George R. Blumenschein,Fabrice Barlesi,Bruno Coudert,Justin F. Gainor,Oscar Arrieta,Julie R. Brahmer,Charles Butts,Martin Steins,William J. Geese,Ang Li,Diane Healey,L. Crinò +25 more
TL;DR: In this article, the anti-programmed death-1 antibody nivolumab versus docetaxel was compared in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous NSCLC.
Journal ArticleDOI
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Thomas Eigentler,Jessica C. Hassel,Carola Berking,Jens Aberle,Oliver Bachmann,Viktor Grünwald,Katharina C. Kähler,Carmen Loquai,Niels Reinmuth,Martin Steins,Lisa Zimmer,Anna Sendl,Ralf Gutzmer +12 more
TL;DR: With regard to the outstanding clinical activity of the anti-PD-1 antibodies, therapy restart is the principal therapeutic option after recovery of grade 2 AEOSI, or diminution of higher grade skin or endocrine events to mild severity.